Osaic Holdings
VYNE icon

Osaic Holdings’s VYNE Therapeutics VYNE Stock Holding History

Osaic Holdings’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6
Closed -$24 – 7552
2023
Q2 		$24 Buy
+6
New +$32 ﹤0.01% 7365
2022
Q1 		– Sell
-28
Closed -$1K – 7524
2021
Q4 		$1K Hold
28
– – ﹤0.01% 7260
2021
Q3 		$1K Sell
28
-25
-47% -$970 ﹤0.01% 7091
2021
Q2 		$3K Buy
53
+28
+112% +$2.22K ﹤0.01% 6635
2021
Q1 		$3K Hold
25
– – ﹤0.01% 6411
2020
Q4 		$3K Hold
25
– – ﹤0.01% 5991
2020
Q3 		$3K Hold
25
– – ﹤0.01% 5766
2020
Q2 		$3K Buy
25
+17
+213% +$2.3K ﹤0.01% 5698
2020
Q1 		$2K Buy
+8
New +$2.51K ﹤0.01% 5737

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings's VYNE Position: Q3 2023 in Review

Osaic Holdings sold out of VYNE Therapeutics (VYNE) in Q3 2023, closing a stake of 6 shares — an estimated $24 sold.

Osaic Holdings first reported a position in VYNE in Q1 2020 and held it in 9 quarters. The position peaked at $3K in Q2 2021. 21 funds tracked by Wall St. Rank hold VYNE as of Q3 2023.

  • Osaic Holdings reported no remaining VYNE Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Osaic Holdings sold 6 VYNE Therapeutics shares in Q3 2023, an estimated $24.
  • Osaic Holdings first reported a position in VYNE Therapeutics in Q1 2020 and held it in 9 quarters.
  • Osaic Holdings's VYNE Therapeutics position peaked at $3K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2023.

Based on Osaic Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.